Study on SSRIs and Breast Cancer Risk
Author Information
Author(s): Janet Ashbury, Linda Lévesque, Patty Beck, Kristan Aronson
Primary Institution: Queen's University
Hypothesis
Does the use of selective serotonin reuptake inhibitors (SSRIs) increase the risk of breast cancer based on duration of use, cumulative dose, and latency?
Conclusion
The study found no association between SSRI use and an increased risk of breast cancer.
Supporting Evidence
- The study included a large sample size of 1,701 cases and 17,017 controls.
- No increased risk of breast cancer was found with prolonged SSRI use.
- The study improved upon previous research by considering specific exposure time windows.
Takeaway
This study looked at whether taking certain antidepressants called SSRIs could lead to breast cancer, and it found that they don't seem to increase the risk.
Methodology
A population-based case-control study using Saskatchewan health databases, comparing 1,701 women with breast cancer to 17,017 controls.
Potential Biases
Potential for misclassification of SSRI use due to reliance on prescription data.
Limitations
The study did not include information on some potential confounders such as reproductive history and lifestyle factors.
Participant Demographics
Women aged 28 to 79, with a mean age of 60.4 years at diagnosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website